Form 4 Immuneering Corp For: 17 March
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immuneering Corp (IMRX)
Track the Immuneering share price today and view real-time IMRX share price data, including charts, technicals, and key financials. View the IMRX premarket stock price ahead of the market session or assess the after hours quote. Explore IMRX stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Immuneering Stock Price Today?
The Immuneering stock price today is 5.750.
What Is the Stock Symbol for Immuneering?
The stock symbol for Immuneering is ""IMRX.""
What Stock Exchange Does Immuneering Trade On?
Immuneering is listed and trades on the NASDAQ stock exchange.
Is Immuneering a Good Stock to Buy?
Determining whether Immuneering or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMRX quote. (ISIN: US45254E1073)
What Is the Immuneering Stock Price Today?
The Immuneering stock price today is 5.750.
What Is the Stock Symbol for Immuneering?
The stock symbol for Immuneering is ""IMRX.""
What Stock Exchange Does Immuneering Trade On?
Immuneering is listed and trades on the NASDAQ stock exchange.
Is Immuneering a Good Stock to Buy?
Determining whether Immuneering or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMRX quote. (ISIN: US45254E1073)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.251
5.750
52 wk Range
1.100
10.080
IMRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.2515.750
52 wk Range
1.10010.080
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
17.000
Upside
+195.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K Immuneering Corp For: 6 March
- Investing.com
- Form 13G Immuneering Corporation For: 22 January
- Investing.com
- Immuneering receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 4 Immuneering Corp For: 17 March
- Investing.com
- Immuneering receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Immuneering receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Compare IMRX to Peers and Sector
Metrics to compare | IMRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | −5.1x | −0.5x | |
PEG Ratio | −0.17 | −0.20 | 0.00 | |
Price/Book | 1.7x | 5.1x | 2.6x | |
Price / LTM Sales | - | 24.4x | 3.2x | |
Upside (Analyst Target) | 168.0% | 78.2% | 45.7% | |
Fair Value Upside | Unlock | −1.4% | 4.8% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.000
(+195.65% Upside)
Earnings
Latest Release
06/03/2026
EPS / Forecast
-0.18 / -0.31
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Immuneering (IMRX) Stock Price Today?
The Immuneering stock price today is 5.750 USD.
What Stock Exchange Does Immuneering Trade On?
Immuneering is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immuneering?
The stock symbol for Immuneering is "IMRX."
What Is the Immuneering Market Cap?
As of today, Immuneering market cap is 371.750M USD.
What Is Immuneering's Earnings Per Share (TTM)?
The Immuneering EPS (TTM) is -1.273.
When Is the Next Immuneering Earnings Date?
Immuneering will release its next earnings report on 12/05/2026.
From a Technical Analysis Perspective, Is IMRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Immuneering Stock Split?
Immuneering has split 0 times.
How Many Employees Does Immuneering Have?
Immuneering has 53 employees.
What is the current trading status of Immuneering (IMRX)?
As of 16/04/2026, Immuneering (IMRX) is trading at a price of 5.750 USD, with a previous close of 5.750 USD. The stock has fluctuated within a day range of 5.251 USD to 5.750 USD, while its 52-week range spans from 1.100 USD to 10.080 USD.
What Is Immuneering (IMRX) Price Target According to Analysts?
The average 12-month price target for Immuneering is 17.000 USD, with a high estimate of 30 USD and a low estimate of 11 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +195.65% Upside potential.
What Is the IMRX After Hours Price?
IMRX's last after hours stock price is 5.510 USD, the stock has decreased by -0.240, or -4.170%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.